Palliative care led by clinical nurse specialists for patients with advanced cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the effectiveness of an oncology clinical nurse specialist-led early intervention multidisciplinary approach to palliative and survivorship care for patients with metastatic solid tumors. It aims to compare patient-reported symptom burden, quality of life, distress, and overall survival between this new model and standard care. The trial will involve 100 adult patients, who will be randomized into treatment groups based on their recruitment setting, either inpatient or outpatient. The study focuses on patients with favorable prognostic curves to assess the impact of specialized care on their overall well-being.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* adult patients (21 yrs and over)
* metastatic solid tumor malignancy with very favorable and favorable prognostic curves
* under the care of GSUH oncology and radiation oncology clinicians

Exclusion Criteria:

* patients with metastatic solid tumor malignancy who are \< 21 yrs of age
* adult patients with metastatic solid tumor malignancy who are in standard risk and unfavorable prognostic curves
* patients not under the care of GSUH oncology and radiation oncology clinicians

Where it's running

• Good Samaritan University Hospital
  West Islip, New York, United States Recruiting

Study contacts

• Study coordinator: Johnny Kao, MD
• Email: Johnny.Kao@chsli.org
• Phone: 631-376-4047

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• HMPL-A830 in solid tumors for adults with unresectable or metastatic cancer

  This first-in-human study tests HMPL-A830 in adults with unresectable or metastatic solid tumors to see how safe it is and how it behaves at varying doses.

  Recruiting at 4 sites Phase 1/2 Hutchmed · Orange, California and 13 other locations · NCT07718581

• Imaging with 89Zr-DFO-YS5 to detect cancer

  This study tests a new PET radiotracer, 89Zr-DFO-YS5, to see if it can show cancer sites in adults with nerve sheath tumors, bladder cancer, or other solid tumors.

  Recruiting Phase 1 University of California, San Francisco · San Francisco, California · NCT07664397

• Luvometinib plus Anlotinib in KRAS-mutated NSCLC

  This study tests whether the combination of luvometinib and anlotinib helps people with KRAS-mutated metastatic non-small cell lung cancer who have tried prior treatments.

  Recruiting Phase 2 Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. · Shanghai, Shanghai Municipality · NCT07562581

• Gefitinib, trametinib, disulfiram, and sunitinib added to standard chemotherapy for metastatic osteosarcoma

  This study tests whether adding gefitinib, trametinib, disulfiram, and sunitinib to standard chemotherapy helps people with newly diagnosed metastatic osteosarcoma.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07477457

• Outcomes for Oligometastatic and Oligorecurrent Cervical Cancer

  This registry will see if adding local treatments such as radiation or surgery to standard systemic therapy helps people with oligo‑metastatic or oligo‑recurrent cervical cancer live longer or avoid progression.

  Recruiting Tata Memorial Hospital · Mumbai, Maharashtra · NCT07400809

• DESCANSO/REST mental health program for Spanish-speaking Latino adults with cancer experiencing depression, insomnia, and fatigue

  This program will test whether a telehealth-delivered DESCANSO/REST intervention can help Spanish-speaking Latino adults with stage I–III solid tumors who are receiving systemic cancer treatment feel less depressed, sleep better, and have less fatigue.

  Recruiting at 8 sites Ponce Medical School Foundation, Inc. · Basking Ridge, New Jersey and 7 other locations · NCT07225088

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.